Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00626678
Other study ID # 87- 01-30 - 6907
Secondary ID
Status Completed
Phase Phase 2
First received February 21, 2008
Last updated November 26, 2010
Start date January 2008
Est. completion date September 2010

Study information

Verified date November 2010
Source Tehran University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Description: Pemphigus vulgaris is an autoimmune, chronic and recurrent blistering disease with unknown etiology that affects mucosa and skin of patients with significant morbidity and mortality.

The treatment back-bone is based on prednisolone administration. There are controversies on the opportunity of adding immunosuppressive drugs. For some, they are just corticosteroid sparing drugs. For others, they are disease modifying drugs.

The purpose of this trial is to compare efficacy and safety of azathioprine vs. placebo in new cases of pemphigus vulgaris treated with prednisolone.


Description:

The purpose of this trial is to compare efficacy and safety of azathioprine vs. placebo in new cases of pemphigus vulgaris treated with prednisolone.

Official Title: Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Azathioprine in New Cases of Pemphigus Vulgaris Receiving Prednisolone

Randomized Double Blind Controlled Trial of Azathioprine versus Placebo in new cases of Pemphigus Vulgaris treated with Prednisolone

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Controlled, Parallel Assignment, Safety/Efficacy Study

Condition Intervention Phase Pemphigus Vulgaris Drug: Azathioprine Drug: Prednisolone Other: Placebo Phase II


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date September 2010
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender All
Age group 10 Years to 75 Years
Eligibility Inclusion Criteria:

- Lesions clinically consistent with pemphigus vulgaris

- Diagnosis confirmed by histology in terms of acantholysis within past month

- Positive DIF

Exclusion Criteria:

- Any nursing or pregnant woman

- Any history of chronic diseases including liver disease, Chronic Renal Failure, Chronic Heart Failure or Ischemic Heart Disease

- Present diagnosis of hepatitis confirmed by serology or elevated hepatic enzymes;

- Clinically significant concurrent medical disease or laboratory abnormalities evidenced by one or more of the following:

- Hepatobiliary AST or ALT = 1.5 × upper limit of normal (ULN);alkaline phosphatase = 1.5 × ULN; or, total bilirubin > 90% of the ULN;

- Renal serum creatinine > 1.5 mg/dL; or, significant proteinuria > 2+ on urinary dip test;

- Hematologic hemoglobin < 11 mg/dL; leukocytes < 3.5 × 109/L; neutrophils < 1.5 × 109/L; or, platelets < 100 × 109/L; Presence of anemia, leukopenia or thrombocytopenia

- Any sign of patient's non-compliance

- Known hypersensitivity to study drugs, prednisone or azathioprine

- Participating in another clinical trial at the time of screening and enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azathioprine
It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
Prednisone
Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
Placebo
Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study

Locations

Country Name City State
Iran, Islamic Republic of Department of Dermatology, Tehran University of Medical Sciences Tehran

Sponsors (1)

Lead Sponsor Collaborator
Tehran University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary • Disease activity index Throughout study; first two weeks every day, then weekly for two weeks, then monthly for eleven months
Secondary Total dose of corticosteroid At the end of study
Secondary Occurence of any adverse event Throughout study
Secondary Occurence of Grade 3 or higher treatment-related adverse event Throughout study
Secondary Adverse events resulting in discontinuation and assessed by the investigators as at least possibly related to treatment Throughout study
See also
  Status Clinical Trial Phase
Recruiting NCT04422912 - A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) Phase 1
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT04117529 - Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus N/A
Completed NCT03334058 - A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus Phase 2
Terminated NCT03239470 - Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus Phase 1
Completed NCT00606749 - Use of KC706 for the Treatment of Pemphigus Vulgaris Phase 2
Terminated NCT00429533 - Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Phase 2
Recruiting NCT05594472 - Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Phase 3
Completed NCT02383589 - A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Phase 3
Withdrawn NCT03780166 - A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris Phase 2
Recruiting NCT04096222 - Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
Not yet recruiting NCT03177213 - Serum IL-21 Levels in Patients With Pemphigus Vulgaris N/A
Completed NCT00135720 - Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris Phase 2
Completed NCT00063752 - Safety Study of PI-0824 to Treat Pemphigus Vulgaris Phase 1
Terminated NCT03075904 - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Phase 1/Phase 2
Terminated NCT04598477 - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) Phase 3
Completed NCT02704429 - A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris Phase 2
Active, not recruiting NCT05338112 - Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
Completed NCT06167408 - Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
Recruiting NCT05303272 - A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV) Phase 4